Vés al contingut

Recerca Biomèdica en Urologia

El grup de Recerca Biomèdica en Urologia està dedicat a l'estudi dels càncers dependents d’hormones, en particular, del càncer de pròstata (però no limitat a aquest). 

Els nostres esforços estan centrats a trobar eines que ens ajudin en el diagnòstic precoç de la malaltia, diferenciar millor els tumors d’acord amb la seva agressivitat i la seva resposta a la teràpia i, finalment, trobar teràpies eficaces contra aquesta. 

Des del punt de vista molecular, centrem els nostres estudis principalment en processos de senyalització cel·lular relacionats amb el cicle cel·lular i la mitosi (amb les cinesines, les cinases i la ubiquitina dependent de lligases com a dianes principals). 

El nostre grup multidisciplinari està compost per biòlegs moleculars i uròlegs, i col·laborem amb oncòlegs, patòlegs i especialistes d’altres malalties quan es requereix. 

Treballem amb dades in silico obtingudes amb diferents tècniques «òmiques», mostres i dades clíniques dels pacients, i models in vitro i in vivo, per respondre a les preguntes plantejades.


Joan Morote Robles

Joan Morote Robles

Cap de grup
Rercerca biomèdica en urologia
Llegir més
Enric Trilla Herrera

Enric Trilla Herrera

Investigador/a principal
Rercerca biomèdica en urologia
Llegir més
Inés de Torres Ramirez

Inés de Torres Ramirez

Rercerca biomèdica en urologia
Llegir més
Ana Celma Domènech

Ana Celma Domènech

Rercerca biomèdica en urologia
Llegir més
Mercè Cuadras Solé

Mercè Cuadras Solé

Rercerca biomèdica en urologia
Llegir més
Enric Miret Alomar

Enric Miret Alomar

Llegir més
Joan Morote Robles

Joan Morote Robles

Cap de grup
Rercerca biomèdica en urologia
Llegir més
Enric Trilla Herrera

Enric Trilla Herrera

Investigador/a principal
Rercerca biomèdica en urologia
Llegir més
Inés de Torres Ramirez

Inés de Torres Ramirez

Rercerca biomèdica en urologia
Llegir més
Ana Celma Domènech

Ana Celma Domènech

Rercerca biomèdica en urologia
Llegir més
Mercè Cuadras Solé

Mercè Cuadras Solé

Rercerca biomèdica en urologia
Llegir més
Enric Miret Alomar

Enric Miret Alomar

Llegir més

Línies de recerca

Bone metastases in prostate cancer (Translational research in prostate cancer)

Once the tumor metastasizes to bone, the metastatic disease become incurable and current therapies are palliative. Thus, to better understand the biology of PC bone metastasis and to investigate new therapeutic options it is crucial to develop new animal models.

We have established new experimental models of PC bone metastasis by inoculation (intratibial and intracardiac) of human PC cell lines in immunodeficient mice to make a suitable model for evaluating novel compounds as future therapeutic approaches. Extensive bone metastases were monitored by in vivo bioluminescence imaging. By applying different strategies we have described new molecular targets involved in the mechanisms of PC bone metastasis.

1) Garcia M, et al. BJU Int. 2014;113:E164-77.

2) Doll A, et al. Arch Esp Urol. 2013;66:463-74.

IP: Joan Morote Robles

Cell Cycle and Cancer.

Principal Investigator

Anna Santamaría Margalef, PhD

Clinical Associated Researchers

Juan Morote Robles, MD, PhD (co-head Biomedical Research Group in Urology)

Jacques Planas, MD, PhD  

PhD Students

Letícia Suárez

Marta Barber


Adrián García

Past members

Dr. Núria Masiá

Dr. Melissa Bradbury (MD)

Dr. Alfonso Parrilla

Dr. Mireia Oliván

Dr. Blanca Majem

Gabriel Tamayo


The efforts of our team are devoted to give answer to the main challenges in the field of cancer (diagnosis, prognosis and therapy), in particular we focus our attention to homone-dependent tumors, namely prostate tumors (but not limited to) and on cell cycle-related signaling pathways, specifically mitosis and the role of key regulatory enzymes (kinesins, kinases and ubiquitin ligases).


Alternative therapeutic strategies based on mitotic regulators: kinesins

Alterations in the expression of several mitotic regulators have been associated with tumor formation in many cancers. Recent genomic studies have shown that androgen receptor (AR) activity in hormone-refractory prostate cancer (PCa) is not identical to that displayed in androgen dependent cells. Interestingly, increasing evidence in the last years suggest that castrated-resistance prostate cancer (CRPC) cells have undergone a genetic reprogramming to upregulate the expression of M-phase cell cycle genes. AR selectively and directly upregulates a set of mitotic regulators to promote androgen independent PCa. Enrichment of M-phase proteins and pathways has been found in CRPC chemotherapy-resistant tumors compared with their chemotherapy-naïve counterparts. In this context, the main goal of this research line is to gain novel molecular insights into the progression of PCa, with special emphasis on the involvement of mitotic regulators in the acquisition of prostate tumors androgen independence. Through a proteomic-based approach we have identified drivers of the castration-resistant disease and several mitotic kinesins stand out. We aim at studying their role as potential as therapeutic targets.

Contribution to disfunctionality of mitotic regulators alterations to CIN in certain tumors

We aim at understanding first, the basic molecular mechanisms by which mitotic players (spindle-associated proteins and mitotic kinases such us hBora, Ska, CHICA, Plk1, Aurora A) that normally operate to ensure the error-free segregation of chromosomes, and how are they regulated in time and space and second, and which mechanisms give rise to the chromosomal instability that is typical of tumor cells by taking advantage of the animal and human models of cancer currently used in the laboratory.

BRCA1 and BRCA2-dependent ubiquitination and phosphorylation landscapes in cancer patients

High-grade serous carcinoma (HGSC) is characterized by presenting defects in the homologous recombination repair, most frequently associated to BRCA1 mutations. Although most patients will initially respond to first-line chemotherapy with platinum-based agents, up to a quarter will be resistant to treatment. In recent years we have advanced in the understanding of HGSC tumour physiology and its dependence on BRCA1 and, secondly, have identified protein signature able to discriminate between chemotherapy resistant and sensitive patients. In collaboration with the clinicians at the Gynecology Department at the Vall Hebron Hospital, we have performed a multi-layered proteomic characterization of patient-derived ovarian tissues, which has revealed the importance of both ubiquitination and phosphorylation layers of regulation in modulating key cellular processes in HGSC, their dependency on BRCA1 and the identification of BRCA1 substrates responsible for driving ubiquitination signalling. Also, using discovery and targeted proteomics in HGSC tissues, we have identified a protein signature able to discriminate between chemotherapy resistant and sensitive patients at the time of cancer diagnosis. Collectively, we have performed a comprehensive molecular characterization of HGSC that provides a groundwork for future mechanistic-based studies and the development of new targeted therapies in ovarian cancer. In addition, we advance in the optimization of therapeutic decision making through the identification of a promising protein signature able to predict response to chemotherapy.

On the other hand, previous sequencing studies revealed that alterations of genes associated with DNA damage response (DDR) are enriched in men with mCRPC. Although BRCA2 mutations are known to confer an increased risk of breast and ovarian cancer, recent observations have shown that alterations of BRCA2 are more prevalent than previously appreciated in men with PCa and more frequent than alterations in any other DDR gene. We aim at translating our expertise and results on BRCA1 related to HGSC, to get deeper insights into the functional relevance of BRCA2 mutations in PCa. In close collaboration with the Urology Deparment at Vall Hebron (Dr. Jacques Planas), we also aim at improving the management of patients with BRCA2 mutations.

Drug development

We are interested in testing the therapeutic potential of new synthetic or natural compounds in clinically representative tumor cell lines (of prostate and ovarian cancer) and preclinical mouse models to improve the efficacy and safety of currently available treatments. 


1. 2019PROD00087, SalivOmiX: Prova basada en la detecció de miRNAs en saliva per el diagnòstic precoç del càncer d'ovari  AGENCIA DE GESTIO D'AJUTS UNIVERSITARIS I DE RECERCA. Producte.  Anna Santamaria Margalef.  (FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL UNIV. VALL D'HEBRON). 01/07/2020-31/12/2021. 100.000 €.

2. PI18/01017,  SalivOmiX: Test basado en el análisis de miRNAs en saliva para la detección precoz del cáncer de ovario   Instituto de Salud Carlos III (FIS). (INSTITUTO DE INVESTIGACION HOSPITAL UNIVERSITARIO VALLE DE HEBRON).  01/2019- 12/2021. 159.720 €. Investigador principal.

3. 2017 SGR 1661,  Grup de Recerca Biomèdica en Ginecologia  AGENCIA DE GESTIO D'AJUTS UNIVERSITARIS I DE RECERCA. SGR.  Anronio Gil Moreno.  (FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL UNIV. VALL D'HEBRON).  01/01/2018- 31/12/2020. 33.000 €. Miembro de equipo.

4. AECC/2017/SANTAMARIA,  Nuevos enfoques terapéuticos para el cáncer de próstata hormono-refractario basados en la kinesina KIF11   Asociación Española Contra el Cáncer. AECC - Junta Barcelona (Conveni ajudes per a la investigació 2017).  Anna Santamaria Margalef. (FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL UNIV. VALL D'HEBRON). 2018-2019. 34.700 €. Investigador principal.

5. 2016 LLAV 00056, Salivomics: identification of genòmic markers to improve early ovarian càncer detection   AGENCIA DE GESTIO D'AJUTS UNIVERSITARIS I DE RECERCA. Llavor. Anna Santamaria Margalef. (FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL UNIV. VALL D'HEBRON). 2017-2018. 20.000 €. Investigador principal.

6. PI15/02238, Sensibilidad a quimioterapia en cáncer de ovario: Plk1 y Aurora A quinasas como terapia alternativa que permitan mejorar la respuesta antitumoral y la estratificación de pacientes  FIS. Anna Santamaria Margalef. (FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL UNIV. VALL D'HEBRON). 2016-2018. 122.815 €. Investigador principal.

7. RTC-2015-3821-1,  Desarrollo de nuevas aproximaciones en el manejo individualizado de pacientes con cáncer ginecológico (PredicareGYN)   Ministerio de Economía y Competitividad. RETOS.  Anna Santamaria Margalef.  (FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL UNIV. VALL D'HEBRON). 2015-2018. 348,6 €. Co-Investigador principal.

8. Transcripció, traducció i mitosi en càncer de pròstata resistent a teràpia.TRAMIT-CAP (GRE)   AGENCIA DE GESTIO D'AJUTS UNIVERSITARIS I DE RECERCA. Grup de Recerca Emergent (SGR-AGAUR). Anna Santamaria Margalef. (FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL UNIV. VALL D'HEBRON). 01/01/2014-31/12/2016. 16.000 €. Co-Investigador principal.

9. CP13/00158,  Characterization of Plk1 alterations and consequences in the progression tumorigenesis, with a focus in prostate cancer   Miguel Servet (FIS).  Anna Santamaria Margalef.  (FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL UNIV. VALL D'HEBRON). 2014-2016. 120.500 €. Investigador principal.

10. Control of chromosome segregation fidelity   Swiss Cancer League. Anna Santamaria Margalef.  (Biozentrum - University of Basel).  02/2011-02/2014.  160.000  €.  Investigador principal.


Atrys (Madrid, Spain)

Oncostellae (Santiago de Compostela, Spain)

4SC (Münich, Germany)


Currently under review:

- Bradbury M; … Gil-Moreno A; Sabidó E*; Santamaria, A*. BRCA1 mutations reshape the signaling landscape in high-grade serous ovarian cancer patients. Science Signalling (under review) (*equal contribution).

- Bradbury M; … Gil-Moreno A; Santamaria, A*; Sabidó E*. Molecular advances for the management of high-grade serous ovarian cancer patients. Cancers (under review) (*equal contribution).

1.- Alfonso Parrilla; Marta Barber; Blanca Majem; et al.,; Miguel F Segura; Antonio Gil Moreno; Anna Santamaria. Aurora Borealis (Bora), Which Promotes Plk1 Activation by Aurora A, Has an Oncogenic Role in Ovarian Cancer. Cancers (Basel). 12 - 4, pp. pii:E886. 06/04/2020. DOI: 10.3390/cancers12040886.

2.- Blanca Majem; Alfonso Parrilla; et al.,; Antonio Gil Moreno; Miguel F Segura; Anna Santamaría. MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC, WNT and AKT pathways. Oncogene. 38 - 32, pp. 6035 - 6050. 08/2019. ISSN 1476-5594 DOI: 10.1038/s41388-019-0860-0

3.- Soriano A; Masanas M; Boloix A; et al; Santamaria A; Segura MF. 2019. Functional high-throughput screening reveals miR-323a-5p and miR-342-5p as a new tumour-suppressive microRNAs in neuroblastoma. Cell Mol Life Sci. 76-11, pp.2231-2243. ISSN 2041-1723.

4.- Óscar Rapado-González, Blanca Majem, et al., Anna Santamaría, Rafael López-López, Laura Muinelo-Romay, María Mercedes Suarez-Cunqueiro. A Novel Saliva-Based miRNA Signature for Colorectal Cancer Diagnosis. J. Clin. Med. 2019, 8, 2029;doi:10.3390/jcm8122029

5.- Óscar Rapado-González, Blanca Majem, Laura Muinelo-Romay, Ana Álvarez-CastroAnna Santamaría , Antonio Gil-Moreno , Rafael López-López , María Mercedes Suárez-CunqueiroHuman salivary microRNAs in Cancer. J Cancer.  2018 Jan 6;9(4):638-649. doi: 10.7150/jca.21180. eCollection 2018.

6.-Devis, L; Moiola, C; Masia, N; et al; Santamaria, A; Colas, E. 2017. Activated leukocyte cell adhesion molecule (ALCAM) is a marker of recurrence and promotes cell migration, invasion and metastasis in early stage endometrioid endometrial cáncer. Journal of Pathology. WILEY-BLACKWELL. 241-4, pp.475-487. ISSN 0022-3417.

7.- A Almazán-MogaP ZarzosaC MolistP Velasco , J PyczekK Simon-KellerI GiraltI VidalN NavarroM F Segura, A SorianoS NavarroO M TiradoJ C FerreresA SantamariaR RotaH HahnJ Sánchez de Toledo , J RomaS Gallego. 2017. Ligand-dependent Hedgehog pathway activation in Rhabdomyosarcoma: the oncogenic role of the ligands. Br J Cancer. 117-9, pp.1314-1325. ISSN 0007-0920. 1

8.- Redli, PM; Gasic, I; Meraldi, P; Nigg, EA; Santamaria, A. The Ska complex promotes Aurora B activity to ensure chromosome biorientation. Journal of Cell Biology. 215 - 1, pp. 77 – 93, 2016. ROCKEFELLER UNIV PRESS, 10/10/2016. ISSN 0021-9525DOI: 10.1083/jcb.201603019

9.- Thomas, Y.; Cirillo, L.; Panbianco, C.; et al; Santamaria, A.; Gotta, M. 2016. Cdk1 Phosphorylates SPAT-1/Bora to Promote Plk1 Activation in C. elegans and Human Cells. Cell Reports. CELL PRESS. 15-3, pp.510-518. ISSN 2211-1247.

10.- Abad, MA; Zou, J; Medina-Pritchard, B; Nigg, EA; Rappsilber, J; Santamaria, A; Jeyaprakash, AA. 2016. Ska3 Ensures Timely Mitotic Progressionby Interacting Directly With Microtubules and Ska1 Microtubule Binding Domain. Scientific Reports. NATURE PUBLISHING GROUP. 6, pp.34042. ISSN 2045-2322.

11.- Maria-Alba* Abad; Medina, B*; Santamaria, A*; Zou, J; Plasberg-Hill, C; Madhumalar, A; Jayachandran, U; Rappsilber, J; Nigg, EA; Jeyaprakash, AA. Structural Basis for the Microtubule-Recognition by the human kinetochore Ska complex. Nature Communications. 5, pp. 2964. NATURE PUBLISHING GROUP, 2015. ISSN 2041-1723 (*equal contribution)

IP: Anna Santamaria Margalef

Cell signaling and cancer progression

Prostate cancer (PC) is the second leading cause of death for cancer in men of the western Countries. While considerable advances have been made in the treatment of localized, organ-confined tumors, metastatic PC is virtually incurable and most deaths from this disease are due to the high resistance of metastasis to conventional therapies (androgen-depletion-therapy, ADT). Therefore, more precise markers for the detection of the incipient resistant tumor and more effective targets that eliminate the resistant clones are needed.

A principal aim is to identify relevant molecular pathways specifically active in aggressive prostate cancer, useful for an early detection of ADT resistant tumors and for treatment strategies.

In our studies, we have discovered the human Prostate Tumor OVerexpressed-1 (PTOV1) gene, later called Acid-2, and a second gene with a PTOV module, PTOV2, later called MED25, a component of Mediator (1-2).

The detection of PTOV1 in high-grade PIN (HGPIN) premalignant lesions is helpful to identify patients with higher probability to develop PC (3). PTOV1 ectopic expression promotes proliferation, invasion and metastasis of ADT resistant cells (1,2,4,5). PTOV1 induces the epithelial-mesenchymal-transition (EMT) and increased metastasis of PC3 cells (4). Mechanistically, PTOV1 is implicated in multiple processes controlling cell fate: it promotes mRNA translation leading to a specific increased synthesis of c-Jun and Snai1 oncogenes (4), and it is a transcriptional repressor of HES1 and HEY1 genes, leading to inhibition of Notch signalling in metastatic PC (5). PTOV1 significantly affect the self-renewal potential of the cancer stem cell populations of PC3 cells (5).  

Current objectives of our line of research are: (i) Determine the role of PTOV1 in the resistance to ADT and chemotherapy (taxols). (ii) Characterize the sub-clonal cancer stem cell populations (CSC) present in metastatic primary tumors and the genes and factors responsible for the development of the resistance to ADT.

1) Benedit P, et al. Oncogene 2001;20:1455–1464.

2) Santamaria A, et al. Am J Pathol 2003;162:897–905.

3) Morote J, et al. Clin Cancer Res 2008:14:2617-2622.

4) Marqués N, et al. Oncogene 2014;33(9):1124-34.

5) Alaña L et al., Mol Cancer 2014;13:74.

IP: Cell signaling and cancer progression

Development of non-invasive methods for the early detection of prostate cancer (Translational research in prostate cancer)

One main focus of our research is the discovery of new biomarkers for the early detection of prostate cancer (PC). The detection of proteins, RNA or miRNAs from easily accessible body fluids, such as blood or urine, will make possible to diagnose the disease at an early/pre-symptomatic stage, or monitoring responses to therapy in a simple and non-invasive way.  This will improve the specificity of the currently used PSA serum measurements.

We have identified a three-gene panel in urine able to increase the PSA specificity for the detection of PC, and using liquid chromatography, mass spectrometry and triple quadruple mass spectrometry (LC/MSMS, SRM), we have discovered the presence of specific, differential proteomic profiles in the urine of PC patients.

Furthermore, we have identified a genomic profile able to detect PC in patients previously diagnosed with high-grade prostatic intraepithelial neoplasia (HGPIN). Such profile should have an application in the clinics and improve decision making in the diagnosis and treatment of PC (Figure).

1) Sequeiros T, et al. Prostate 2015; Accepted;

2) Rigau M*, Olivan M*, et al. Int. J. Mol. Sci. 2013;14: 12620-12649;

3) Rigau M, et al. Prostate 2011; 71:1736-45;

4) Rigau M et al. Prostate 2010; 70:1760-7

IP: Joan Morote Robles


Incorporación de métodos de imagen y perfiles moleculares para mejorar el cribado de cáncer de próstata en portadores de mutaciones en genes de las vías de reparación de ADN.

IP: Olga Méndez Fernández
Col·laboradors: Berta Miró Cau, Marc Simo Perdigo, David Ruiz Casajuana, Jacques Planas Morin, Richard Mast
Entitat finançadora: Instituto de Salud Carlos III
Finançament: 127500
Referència: PI23/01310
Durada: 01/01/2024 - 31/12/2026

Immunological reset to overcome alloimmune memory in Highly sensitized patients

IP: Oriol Bestard Matamoros
Col·laboradors: Ana Pérez González, Francesc Bosch Albareda, Francesc Moreso Mateos, Enric Trilla Herrera, Joana Sellarés Roig, Irina Betsabe Torres Rodriguez, Enric Miret Alomar, Manel Perelló Carrascosa, Nestor Gabriel Toapanta Gaibor, Maria Antonia Emilia Meneghini, Delphine Kervella, Elena Isabel Crespo Gimeno
Entitat finançadora: Fundación Invest. Médica Mutua Madrileña
Finançament: 109725
Durada: 15/09/2023 - 14/09/2025

KidneyColor: machine learning sobre fotografía digital macroscópica para la predicción de la funcionalidad del trasplante renal de cadáver

IP: Enric Trilla Herrera
Col·laboradors: -
Entitat finançadora: Asociación Española de Urología
Finançament: 25000
Referència: FIU2022/TRILLA
Durada: 29/07/2023 - 28/07/2025

FLUTE: Federate Learning and mUlti-party computation Techniques for prostatE cancer

IP: Olga Méndez Fernández
Col·laboradors: Berta Miró Cau, Alejandro López Targa, Enric Trilla Herrera
Entitat finançadora: EUROPEAN COMMISSION
Finançament: 490375
Referència: FLUTE_HE-HLTH22
Durada: 01/05/2023 - 30/04/2026


Stratifying the initial prostate cancer suspicion to avoid magnetic resonance exams by sequencing men according to serum prostate-specific antigen, digital rectal examination and the prostate-specific antigen density based on digital rectal prostate volume category.

PMID: 37025471
Revista: BJUI compass
Any: 2023
Referència: BJUI Compass. 2022 Dec 28;4(3):266-268. doi: 10.1002/bco2.211. eCollection 2023 May.
Factor d'impacte:
Tipus de publicació: Article en revista internacional
Autors: Abascal, Jose M; Campistol, Miriam; Morote, Juan; Servian, Pol; Trilla, Enrique; Triquell, Marina et al.
DOI: 10.1002/bco2.211

Sex and gender differences in acute stroke care: metrics, access to treatment and outcome. A territorial analysis of the Stroke Code System of Catalonia.

PMID: 37231687
Revista: European Stroke Journal
Any: 2023
Referència: Eur Stroke J. 2023 Jun;8(2):557-565. doi: 10.1177/23969873231156260. Epub 2023 Mar 2.
Factor d'impacte:
Tipus de publicació: Article en revista internacional
Autors: Abilleira, Sonia; Almendros, Mari Cruz; Canovas, David; Carrion, Dolors; Catena, Esther; Cocho, Dolores; Colom, Carla; Costa, Xavier; Deulofeu, Anna; Diaz, Gloria et al.
DOI: 10.1177/23969873231156260

Are magnetic resonance imaging and targeted biopsies needed in men with serum prostate-specific antigen over 10 ng/ml and an abnormal digital rectal examination?

PMID: 37244767
Any: 2023
Referència: Urol Oncol. 2023 May 25:S1078-1439(23)00161-8. doi: 10.1016/j.urolonc.2023.05.003.
Factor d'impacte:
Tipus de publicació: Article en revista internacional
Autors: Abascal, Jose M; Asiain, Ignacio; Celma, Anna; de Manuel, Gemma Garcia; Morote, Juan; Munoz-Rivero, Marta V; Munoz-Rodriguez, Jesus; Paesano, Nahuel; Picola, Natalia; Ruiz-Plazas, Xavier et al.
DOI: 10.1016/j.urolonc.2023.05.003

Metastatic solid tumors to the testis: a clinicopathologic evaluation of 157 cases from an international collaboration.

PMID: 37331529
Any: 2023
Referència: Hum Pathol. 2023 Jun 16:S0046-8177(23)00135-1. doi: 10.1016/j.humpath.2023.06.002.
Factor d'impacte:
Tipus de publicació: Article en revista internacional
Autors: Acosta, Andres M; Akgul, Mahmut; Alvarado-Cabrero, Isabel; Aron, Manju; Celada, Manuel Manrique; Cheng, Liang; Chou, Angela; Collins, Katrina; Contreras, Felix; de Torres, Ines et al.
DOI: 10.1016/j.humpath.2023.06.002

Behavior of SelectMDx and Prostate-specific Antigen Density in the Challenging Scenario of Prostate Imaging-Reporting and Data System Category 3 Lesions.

PMID: 34602313
Any: 2022
Referència: Eur Urol. 2022 Jan;81(1):124-125. doi: 10.1016/j.eururo.2021.09.019. Epub 2021 Sep 30.
Factor d'impacte: 20.096
Tipus de publicació: Carta amb FI
Autors: Morote, Juan; Diaz, Fernando; Celma, Anna; Planas, Jacques; Trilla, Enrique et al.
DOI: 10.1016/j.eururo.2021.09.019

Multidisciplinary Consensus on the Prevention and Treatment of Osteoporosis and Fragility Fractures in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy.

PMID: 34983087
Revista: World Journal of Mens Health
Any: 2022
Referència: World J Mens Health. 2022 Jan;40(1):74-86. doi: 10.5534/wjmh.210061.
Factor d'impacte: 5.4
Tipus de publicació: Revisió en revista internacional
Autors: Casado, Enrique; Borque-Fernando, Angel; Caamano, Manuel; Grana, Jenaro; Munoz-Rodriguez, Jesus; Morote, Juan et al.
DOI: 10.5534/wjmh.210061

Is Tumor Budding a New Predictor for Early Cystectomy in pT1 High-Grade Bladder Cancer?

PMID: 34352790
Any: 2022
Referència: Urol Int. 2022;106(2):154-162. doi: 10.1159/000517543. Epub 2021 Aug 5.
Factor d'impacte: 2.089
Tipus de publicació: Article en revista internacional
Autors: Raventos Busquets, Carles X; Semidey, M Eugenia; Lozano Palacio, Fernando; Carrion Puig, Albert; Aula Olivar, Ana; De Torres Ramirez, Ines M; Trilla Herrera, Enrique et al.
DOI: 10.1159/000517543

Experience and results after the implementation of a radiology day unit in a reference hospital.

PMID: 35767122
Revista: Insights into Imaging
Any: 2022
Referència: Insights Imaging. 2022 Jun 29;13(1):109. doi: 10.1186/s13244-022-01251-2.
Factor d'impacte: 5.231
Tipus de publicació: Article en revista internacional
Autors: Escobar, Manuel; Tomasello, Alejandro; Perez Lafuente, Mercedes; Andreu, Jordi; Grinon, Jesus; Sanchez-Tirado, Cristina; Mast, Richard; Antolin, Andreu; Roson, Nuria et al.
DOI: 10.1186/s13244-022-01251-2

Loss of microRNA-135b Enhances Bone Metastasis in Prostate Cancer and Predicts Aggressiveness in Human Prostate Samples.

PMID: 34944822
Revista: Cancers
Any: 2021
Referència: Cancers (Basel). 2021 Dec 9;13(24). pii: cancers13246202. doi: 10.3390/cancers13246202.
Factor d'impacte: 6.639
Tipus de publicació: Article en revista internacional
Autors: Santamaria, Anna, Rodriguez-Barrueco, Ruth, Morote, Juan, de la Cruz, Xavier, Olivan, Mireia, Garcia, Marta, Suarez, Leticia, Guiu, Marc, Gros, Laura, Mendez, Olga et al.
DOI: 10.3390/cancers13246202

The position of urethrovesical anastomosis after robotic radical prostatectomy assessed by MRI predicts early functional recovery: A cohort analyses from a randomized clinical trial.

PMID: 33607371
Any: 2021
Referència: Eur J Radiol. 2021 Apr;137:109589. doi: 10.1016/j.ejrad.2021.109589. Epub 2021 Feb 12.
Factor d'impacte: 3.528
Tipus de publicació: Article en revista internacional
Autors: Salazar, Aina, Planas, Jacques, Celma, Ana, Cuadras, Merce, Roche, Sarai, Mast, Richard, Morote, Juan, Trilla, Enrique, Regis, Lucas et al.
DOI: 10.1016/j.ejrad.2021.109589

Autophagy Takes Center Stage as a Possible Cancer Hallmark.

PMID: 33194736
Revista: Frontiers in Oncology
Any: 2020
Referència: Front Oncol. 2020 Oct 22;10:586069. doi: 10.3389/fonc.2020.586069. eCollection 2020.
Factor d'impacte: 4.848
Tipus de publicació: Revisió en revista internacional
Autors: Kondoh, Hiroshi, Alvarez-Meythaler, Jose G, Garcia-Mayea, Yoelsis, Mir, Cristina, LLeonart, Matilde E et al.
DOI: 10.3389/fonc.2020.586069

STK11 (LKB1) missense somatic mutant isoforms promote tumor growth, motility and inflammation.

PMID: 32647375
Revista: Communications Biology
Any: 2020
Referència: Commun Biol. 2020 Jul 9;3(1):366. doi: 10.1038/s42003-020-1092-0.
Factor d'impacte: 4.165
Tipus de publicació: Article en revista internacional
Autors: Granado-Martinez, Paula, Garcia-Ortega, Sara, Gonzalez-Sanchez, Elena, McGrail, Kimberley, Selgas, Rafael, Grueso, Judit, Gil, Rosa, Naldaiz-Gastesi, Neia, Rhodes, Ana C, Hernandez-Losa, Javier et al.
DOI: 10.1038/s42003-020-1092-0

Clinical Implications of Extracellular HMGA1 in Breast Cancer.

PMID: 31779212
Any: 2019
Referència: Int J Mol Sci. 2019 Nov 26;20(23):5950. doi: 10.3390/ijms20235950.
Factor d'impacte:
Tipus de publicació: Article en revista internacional
Autors: Cortes, Javier; Mendez, Olga; Perez, Jose; Racca, Fabricio; Soberino, Jesus; Villanueva, Josep et al.
DOI: 10.3390/ijms20235950

A Novel Saliva-Based miRNA Signature for Colorectal Cancer Diagnosis.

PMID: 31757017
Revista: Journal of Clinical Medicine
Any: 2019
Referència: J Clin Med. 2019 Nov 20;8(12). pii: jcm8122029. doi: 10.3390/jcm8122029.
Factor d'impacte: 5.688
Tipus de publicació: Article en revista internacional
Autors: Rapado-Gonzalez, Oscar, Majem, Blanca, Alvarez-Castro, Ana, Diaz-Pena, Roberto, Abalo, Alicia, Suarez-Cabrera, Leticia, Gil-Moreno, Antonio, Santamaria, Anna, Lopez-Lopez, Rafael, Suarez-Cunqueiro, Maria Mercedes et al.
DOI: 10.3390/jcm8122029

MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC, WNT and AKT pathways.

PMID: 31278368
Any: 2019
Referència: Oncogene. 2019 Aug;38(32):6035-6050. doi: 10.1038/s41388-019-0860-0. Epub 2019 Jul 5.
Factor d'impacte: 6.634
Tipus de publicació: Article en revista internacional
Autors: Majem, Blanca, Parrilla, Alfonso, Jimenez, Carlos, Suarez-Cabrera, Leticia, Barber, Marta, Marin, Andrea, Castellvi, Josep, Tamayo, Gabriel, Moreno-Bueno, Gema, Ponce, Jordi et al.
DOI: 10.1038/s41388-019-0860-0

Challenges and opportunities for cell line secretomes in cancer proteomics.

PMID: 25418557
Revista: Proteomics Clinical Applications
Any: 2015
Referència: Proteomics Clin Appl. 2015 Apr;9(3-4):348-57. doi: 10.1002/prca.201400131. Epub 2015 Feb 10.
Factor d'impacte:
Tipus de publicació: Article en revista internacional
Autors: Mendez, Olga; Villanueva, Josep et al.
DOI: 10.1002/prca.201400131

Unconventional secretion is a major contributor of cancer cell line secretomes.

PMID: 23268930
Any: 2013
Referència: Mol Cell Proteomics. 2013 May;12(5):1046-60. doi: 10.1074/mcp.M112.021618. Epub 2012 Dec 26.
Factor d'impacte:
Tipus de publicació: Article en revista internacional
Autors: Baselga, Jose; Gregori, Josep; Mendez, Olga; Salvans, Candida; Villanueva, Josep; Villarreal, Laura et al.
DOI: 10.1074/mcp.M112.021618


Unveiling the role of BORA in ovarian cancer dissemination: a new potential targeted therapeutic strategy

Doctorand: Marta Barber Servera
Director/s: Anna Santamaria Margalef
Universitat: Universitat Autònoma de Barcelona
Any: 2023

Estudio experimental para evaluar si la reconstrucción posterior del rabdoesfínter mejora la continencia urinaria precoz después de la prostatectomía radical robótica (Proyecto RABDO-PROST)

Doctorand: Aina Salazar Gabarro
Director/s: Joan Morote Robles, Lucas Regis Plácido
Universitat: Universitat Autònoma de Barcelona
Any: 2022

Ús d'una matriu de col·lagen i elastina en la reparació d'un defecte vesical amb peritoneu parietal en model porcí

Doctorand: Carlos Gasanz Serrano
Director/s: Joan Morote Robles, Carles Xavier Raventós Busquets
Universitat: Universidad Autònoma de Barcelona
Any: 2018

The role of the oncogene Prostate Tumor Overexpressed-1 and the regulation of mRNA translation in Prostate Cancer progression and chemoresistance

Doctorand: Verónica Cánovas Hernández
Director/s: Rosanna Paciucci Barzanti
Universitat: Universidad Autònoma de Barcelona
Any: 2017

Valoracion del daño renal producido por el neumoperitoneo en un modelo experimental

Doctorand: Ana Celma Domènech
Director/s: Jaume Reventós Puigjaner, Joan Morote Robles
Universitat: Universidad Autònoma de Barcelona
Any: 2009



El treball dirigit pel Dr. Regis demostra que realitzar una reconstrucció robòtica després de la prostatectomia radical es relaciona amb un millor control de l'orina.

Un assaig clínic amb el prototip del dispositiu mostra que l’ús d’aquesta tecnologia millora el control dels pacients per part d’infermeria i redueix les complicacions postquirúrgiques.

Un any més, ens unim al moviment Movember per conscienciar de la necessitat de la recerca per millorar la salut masculina i, en especial, la de pacients amb càncer de pròstata.

Ofertes de treball

Postdoctoral researcher_Biomedical Research in Urology_20240116
Data d'inici:
Data de fi:
Document: Descarrega
Project manager _ Group in Urology
Data d'inici:
Data de fi:
Document: Descarrega
Licensed Technician - Biomedical Research Group in Urology
Data d'inici:
Data de fi:
Document: Descarrega